Session » Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2508

A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2504

A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population

9:00AM-11:00AM: Abstract Number: 2461

Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2476

Analysis of the Disease Activity and Functional Measures of Young Patients with Rheumatoid Arthritis Undergoing Total Joint Arthroplasty By Using the Database of Nation-Wide Observational Cohort

9:00AM-11:00AM: Abstract Number: 2500

Association between Anti-Citrullinated Protein Antibody Status, Erosive Disease and Healthcare Resource Utilization in Patients with RA

9:00AM-11:00AM: Abstract Number: 2457

Association between Biologic Dmards and Weight Change in Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2488

Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results of an International Survey

9:00AM-11:00AM: Abstract Number: 2465

Characterizing Palindromic Symptoms in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study

9:00AM-11:00AM: Abstract Number: 2464

Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2487

Comparison of QOL Evaluation Using EQ-5D-3L and EQ-5D-5L in Japanese RA Patients: A Study Using the IORRA Cohort

9:00AM-11:00AM: Abstract Number: 2485

Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2448

Correlation between Long-Term Low-Dose Steroid Administration and Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2496

Determination of the Minimally Important Difference for Interpreting the RA Multi-Biomarker Disease Activity Test Score: Impact of Diurnal and Daily Biomarker Variation on Scores Adjusted for Age, Sex and Adiposity

9:00AM-11:00AM: Abstract Number: 2474

Development of a Crosswalk for FACIT-10 (Psychometric Work)

9:00AM-11:00AM: Abstract Number: 2501

Disease Activity Is the Major Discriminator When Defining Refractory Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2478

Do Age and Education Influence the Disease Activity Score? an Explorative Analysis in the Norwegian Register of Dmards

9:00AM-11:00AM: Abstract Number: 2469

Early Referral and Flare´s Control Prevent Orthopaedic and Hand Surgery Indication in a Dynamic Cohort of Hispanic Early Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2484

Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2462

Efficacy and Safety in the Middle-LONG Period of Rituximab in the Treatment of Diffuse Interstitial Pulmonary Disease Associated with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2493

Features of Disease Severity Associated with Patient Satisfaction with Biologic Treatment: Results from the Abatacept Best Care Real-World Study

9:00AM-11:00AM: Abstract Number: 2507

Healthcare Resource Utilization in Patients with Secondary Sjögren’s Syndrome Associated with RA Compared with Patients with RA in an Insured Population

9:00AM-11:00AM: Abstract Number: 2451

Herpes Zoster in Rheumatoid Arthritis. Prospective Single Center Study of 390 RA Patients for 5 YEARS

9:00AM-11:00AM: Abstract Number: 2503

Impact of Tobacco Smoking on 1-Year Mortality Following Total Hip and Total Knee Arthroplasty Among Rheumatoid Arthritis Patients – a Danish Cohort Study Using Nationwide Health Care Registers

9:00AM-11:00AM: Abstract Number: 2489

In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome

9:00AM-11:00AM: Abstract Number: 2452

Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2502

Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis

9:00AM-11:00AM: Abstract Number: 2447

Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs

9:00AM-11:00AM: Abstract Number: 2483

Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials

9:00AM-11:00AM: Abstract Number: 2459

Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy

9:00AM-11:00AM: Abstract Number: 2480

Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group

9:00AM-11:00AM: Abstract Number: 2492

Pattern Shift and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China

9:00AM-11:00AM: Abstract Number: 2479

Pilot Study of Characterizing Rheumatoid Arthritis Related Morning Stiffness

9:00AM-11:00AM: Abstract Number: 2458

Predictors of Hypogammaglobulinemia during Rituximab Maintenance Therapy in Rheumatoid Arthritis: A 12-Year Longitudinal Multi-Center Study

9:00AM-11:00AM: Abstract Number: 2499

Predictors of Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-Years Follow-up Study

9:00AM-11:00AM: Abstract Number: 2449

Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry

9:00AM-11:00AM: Abstract Number: 2466

Prolonged Delay in Presentation to Rheumatologists for Hispanic Patients with Rheumatoid Arthritis Contributes to Later Diagnosis and Treatment

9:00AM-11:00AM: Abstract Number: 2475

Promis Pain Interference 6b and Fatigue 7a Short Forms and Profile-29 in Rheumatoid Arthritis Patients Treated with TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 2481

Proposal to Re-Evaluate the Definition of Low Disease Activity in Routine Assesment of Patient Index Data 3 (RAPID3) in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2450

Prosthetic Joint Infection in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2467

RAPID3 Is Elevated in 93% of Treatment-Naïve Rheumatoid Arthritis (RA) Patients at Initial Visit Compared to 49% for Erythrocyte Sedimentation Rate (ESR) and 44% for C-Reactive Protein (CRP)

9:00AM-11:00AM: Abstract Number: 2490

Real World Evidence Describing Infliximab Utilization Patterns in Rheumatoid Arthritis Patients in Community Rheumatology Practices in the United States: Implications for Cost Efficiencies?

9:00AM-11:00AM: Abstract Number: 2486

Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry

9:00AM-11:00AM: Abstract Number: 2463

Reducing Time to Treatment in Patients with Early and Uncontrolled RA: Implementation of a Collaborative and Systems-Based Approach to Improve Access to Care

9:00AM-11:00AM: Abstract Number: 2494

Relationship between Specific Joint Involvement and Work/Activity Impairment in Rheumatoid Arthritis Patients: Implications for Clinical Practice

9:00AM-11:00AM: Abstract Number: 2456

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards

9:00AM-11:00AM: Abstract Number: 2455

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards

9:00AM-11:00AM: Abstract Number: 2495

Sex Differences in the Achievement of Remission in Rheumatoid Arthritis – Choice of Disease Activity Measure Matters

9:00AM-11:00AM: Abstract Number: 2505

Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2453

Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics

9:00AM-11:00AM: Abstract Number: 2460

Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2498

The Association of Vitamin D with the Lipid Profile in Rheumatoid Arthritis: An Interplay Among Genetic Polymorphisms, DHCR7 Levels and Seasonality

9:00AM-11:00AM: Abstract Number: 2446

The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate

9:00AM-11:00AM: Abstract Number: 2445

The Effect of Biologic Agents on Hemoglobin Levels of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2472

The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2470

The Impact of Frailty on Changes in Physical Function Among Adults with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2506

The Joint Disease Burden in Patients with Secondary Sjögren’s Syndrome and RA Compared to Patients with RA Only

9:00AM-11:00AM: Abstract Number: 2473

The Relation between Inflammatory Joint Activity and Disability Related to the Lower Extremities in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2497

The Relationship between Difficulty Affording Arthritis Medications and Illness Intrusiveness in Rheumatoid Arthritis Patients: A Longitudinal Study

9:00AM-11:00AM: Abstract Number: 2444

The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with/without Prior Cancers

9:00AM-11:00AM: Abstract Number: 2482

The Use of Any Conventional Synthetic DMARD Is Associated with Better Indexes of the Physical Component Evaluated By 12-Item Short-Form Health Survey : Analysis of a Cohort of RA Patients

9:00AM-11:00AM: Abstract Number: 2491

Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 2443

Trends in the Incidence of Lymphomas and Leukemias in Patients with Rheumatoid Arthritis in Spain: An Observational Cohort Study of Hospital Discharges from 1999 to 2015

9:00AM-11:00AM: Abstract Number: 2471

Validation of the Functional Index for Hand Osteoarthritis (FIHOA) in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2454

Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib

9:00AM-11:00AM: Abstract Number: 2477

Which Is the Best Measure for Rheumatoid Arthritis Disease Activity? a Head to Head Comparison of the Six American College of Rheumatology Recommended Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 2468

Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].